<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2959">
  <stage>Registered</stage>
  <submitdate>20/10/2010</submitdate>
  <approvaldate>20/10/2010</approvaldate>
  <nctid>NCT01226563</nctid>
  <trial_identification>
    <studytitle>IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction</studytitle>
    <scientifictitle>A Placebo Controlled , Multicenter, Randomized, Double Blind Trial to Evaluate the Safety and Effectiveness of IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction - Preservation I Trial</scientifictitle>
    <utrn />
    <trialacronym>PRESERVATION 1</trialacronym>
    <secondaryid>IK-5001-VENREM-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Myocardial Infarction</healthcondition>
    <healthcondition>Congestive Heart Failure</healthcondition>
    <healthcondition>ST-Elevation Myocardial Infarction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Sodium Alginate and Calcium Gluconate
Treatment: devices - Saline Solution

Experimental: IK-5001 - IK-5001 is a aqueous mixture of sodium alginate and calcium gluconate. A 4 mL (+/- 0.2 mL)slow bolus, intracoronary injection of IK-5001 will be administered over 30 to 60 seconds

Placebo Comparator: Saline Solution - A 4 mL (+/- 0.2 mL)slow bolus intracoronary injection of saline solution will be administered over 30 to 60 seconds


Treatment: devices: Sodium Alginate and Calcium Gluconate
4 mL (+/- 0.2 mL)administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.

Treatment: devices: Saline Solution
4 mL (+/- 0.2 mL)slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Left Ventricular End Diastolic Volume Index - Anatomic measurement of left ventricular end diastolic volume index (LVEDVI) assessed through echocardiogram.</outcome>
      <timepoint>Baseline, 6 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Kansas City Cardiomyopathy Questionaire - Patient reported outcomes (PROs) using The Kansas City Cardiomyopathy Questionaire (KCCQ) score - a validated disease-specific self-administered 23-item questionnaire that will be used to quantify symptoms, function, and quality of life of subjects.</outcome>
      <timepoint>Baseline (prior to index STEMI), 1, 3, 6 and 12 month follow-up visits</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Six minute walk test - The six minute walk test (6MWT) is used for measuring the response to medical interventions in subjects with moderate to severe heart disease, functional status of subjects, as well as a predictor of morbidity and mortality</outcome>
      <timepoint>Baseline (prior to discharge STEMI), 1, 3, 6 and 12 month follow-up visits</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>New York Heart Association (NYHA) functional classification (Physician reported) - New York Heart Association (NYHA) classification assessed by physician will be categorized by Class (Class I - IV)</outcome>
      <timepoint>Baseline (prior to index STEMI), 1, 3, 6 and 12 month follow-up visits</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular death, non-fatal heart failure events or cardiovascular hospitalizations - Time to cardiovascular death, non-fatal heart failure events or cardiovascular hospitalizations adjudicated by a Clinical Events Committee</outcome>
      <timepoint>5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Re-hospitalization due to any cardiovascular event - Time to re-hospitalization due to any cardiovascular event</outcome>
      <timepoint>5 Years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

        Subjects must meet all of the following inclusion criteria to participate in this trial:

          1. The subject is = 18 years of age.

          2. The subject has given informed consent.

          3. The subject has experienced a large STEMI defined by the following criteria:

             Peak cardiac enzyme value within 48 hours of symptom onset as follows:

               -  Creatine kinase MB fraction (CK-MB) &gt; 30 x the upper limit of normal OR

               -  Troponin I &gt; 200 x upper limit of normal OR

               -  Troponin T &gt; 60 x the upper limit of normal

             AND at least 1 of the following 3 criteria:

               -  Delayed presentation with PCI &gt; 6 hours from onset of symptoms

               -  Significant new Q waves in = 2 anterior leads or anterior ST segment elevation of
                  at least 3 mm persistent at 24 hours after PCI

               -  New onset of CHF (Killip class 3-4) or cardiogenic shock persistent at 24 hours
                  after PCI

             AND at least 1 of the following 2 criteria:

               -  MI = 20% by Single Photon Emission Computed Tomography scan (SPECT) or cardiac
                  Magnetic Resonance Imaging (MRI) with defect in the appropriate distribution

               -  Ejection fraction = 35% with wall motion abnormality in the appropriate
                  distribution at baseline imaging assessment

          4. The subject has had successful PCI with stent within 48 hours of symptom onset, and
             residual stenosis less than 20% in the infarct related artery and greater than or
             equal to thrombolysis in myocardial infarction (TIMI) 2 flow. Subjects undergoing
             rescue PCI after thrombolysis or delayed presentation with ongoing ischemia may be
             enrolled.

          5. For Germany only: Patients determined to have Killip class 4 at time of device
             deployment are not eligible for randomization.

          6. For Germany only: If SPECT is used for determination of MI size in order to meet
             inclusion criteria, the SPECT must have been previously performed as part of standard
             clinical care. SPECT is not to be performed solely to qualify a patient for this study
             in Germany.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

        Subjects will be excluded from participating in this trial if ANY of the following
        exclusion criteria are met:

          1. Any subject with cardiogenic shock requiring mechanical ventilation or mechanical
             support at the time of deployment. Subject must be off mechanical support prior to
             deployment.

          2. Need for urgent coronary artery bypass graft (CABG)

          3. Clinically significant valvular heart disease with planned surgical correction or
             transcatheter aortic valve implantation (TAVI)

          4. Uncontrolled ventricular arrhythmias

          5. Renal insufficiency with a calculated creatinine clearance of less than 30 mL/ minute.
             See Appendix A for determining estimated creatinine clearance.

          6. Clinically significant hepatic insufficiency

          7. Inadequate imaging windows (defined as the inability to visualize the endocardial
             border of at least 16 of the 17 segments in both the apical four chambers and apical
             two chamber views without foreshortening) or arrhythmia that would preclude adequate
             3D imaging on transthoracic echocardiography at the local baseline echo assessment

          8. Non-ambulatory prior to the index MI

          9. The subject has participated in another trial of an investigational agent within 30
             days prior to randomization.

         10. Subject has received resorbable stent as part of PCI.

         11. The subject is pregnant or breastfeeding. Women of child-bearing potential will have a
             negative urine pregnancy test prior to randomization.

         12. Any other concurrent condition that, in the opinion of the investigator, would prevent
             completion of the clinical trial, including inability to comply with follow up
             requirements.

         13. For Germany only: In the investigator's opinion, the patient is not expected to
             survive =12 months.

         14. For Germany only: 24 hours prior to device deployment, the patient has a serum calcium
             level greater than the upper limit of normal as determined by the local laboratory.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>306</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA</recruitmentstate>
    <hospital>Gold Coast Hospital - Southport</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba, Brisbane</hospital>
    <hospital>The Queen Elisabeth Hospital - Woodville South</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Alfred Hospital - Melbourne, Victoria</hospital>
    <hospital>The Northern Hospital - Melbourne, Victoria</hospital>
    <hospital>Royal Perth Hospital - Dept. of Cardiology - Perth</hospital>
    <postcode>4215 - Southport</postcode>
    <postcode>4102 - Woolloongabba, Brisbane</postcode>
    <postcode>5011 - Woodville South</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3004 - Melbourne, Victoria</postcode>
    <postcode>3076 - Melbourne, Victoria</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto, Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brive la Gaillarde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble Cedex 09</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Haute Normandie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lubeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ludwigshafen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neuss</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Oldenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Siegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Trier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuppertal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Afula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdnask</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krak√≥w</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Huelva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bellerophon BCM LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective is to evaluate the safety and effectiveness of the IK-5001 device for
      the prevention of ventricular remodeling and congestive heart failure when administered to
      subjects who had successful percutaneous coronary intervention with stent placement after ST
      segment elevation MI (STEMI).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01226563</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Reinilde Heyrman, M.D.</name>
      <address>Bellerophon BCM LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>